title: Determinants of the inhibitory action of purified 14-kDa phospholipases A2 on cell-free prothrombinase complex.
abstract: It has been suggested (Kini, R. R., and Evans, H. J. (1987) J. Biol. Chem. 262, 14402-14407) that the anticoagulant activity of members of the 14-kDa phospholipase A2 (PLA2) family depends on the presence of basic residues within a variable surface region (residues 54-77) distinct from both the conserved catalytic machinery and surface sites mediating the antibacterial action of these enzymes (see Weiss, J., Inada, M., Elsbach, P., and Crowl, R. M. (1994) J. Biol. Chem. 269, 26331-26337). To further define the determinants of the anticoagulant activity of PLA2, we have analyzed the inhibitory effects of purified native and recombinant PLA2 on cell-free prothrombinase. Both native and recombinant wild-type pig pancreas (net charge -1) and human "secretory" PLA2 (net charge +15) produced similar dose-dependent inhibition of prothrombinase activity that was significantly less potent than a toxic PLA2 purified from snake venom. Site-specific mutations that either increased or decreased PLA2 activity toward bactericidal/permeability-increasing protein-treated Escherichia coli by up to 50-fold had no effect on antiprothrombinase activity. In contrast, substitution of Arg for Asp-59/Gly for Ser-60 in the pig PLA2 increased antiprothrombinase activity by 5-10-fold without affecting catalytic activity toward a range of phospholipid substrates or antibacterial activity. Comparison of antiprothrombinase activity of catalytically active and inactive forms of the PLA2 and under a range of phospholipid conditions revealed that the potent antiprothrombinase activity of native toxic venom PLA2 and of the D59R.S60G mutant pancreatic PLA2 reflect combined catalytic and noncatalytic actions, the latter apparently dependent on basic residues at discrete surface sites in the enzyme.
authors.affiliation: Department of Microbiology, New York University School of Medicine, New York 10016.
authors.forename: M
authors.initials: M
authors.lastname: Inada
authors.forename: R M
authors.initials: RM
authors.lastname: Crowl
authors.forename: A C
authors.initials: AC
authors.lastname: Bekkers
authors.forename: H
authors.initials: H
authors.lastname: Verheij
authors.forename: J
authors.initials: J
authors.lastname: Weiss
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology; D008970:Molecular Weight; D010741:Phospholipases A / Q000737:chemistry / Q000494:pharmacology*; D054467:Phospholipases A2; D011994:Recombinant Proteins / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013925:Thromboplastin / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D011994:Recombinant Proteins; D013925:Thromboplastin; D010741:Phospholipases A; D054467:Phospholipases A2